Skip to main content
Fig. 1 | Stem Cell Research & Therapy

Fig. 1

From: Short-course rapamycin treatment enables engraftment of immunogenic gene-engineered bone marrow under low-dose irradiation to permit long-term immunological tolerance

Fig. 1

Rapamycin administration enables long-term multilineage engraftment of antigen-encoding BM under immune-preserving conditions. a, b Titrated doses of MII.OVA BM (5 × 106, 107, 2 × 107 and 5 × 107 cells) mice were transferred i.v. to B6.SJL mice under low-dose (300 cGy) irradiation. At designated time-points, engraftment was determined in peripheral blood leukocytes (PBL) by flow cytometry. cj BM (107 cells) from non-Tg, MII.OVA and actin.OVA mice was transferred i.v. to B6.SJL mice under low-dose irradiation (300 cGy TBI). Rapamycin or PBS was administered i.p. for 22 days commencing at BM transfer. Engraftment was determined for total leukocytes (c) or leukocyte subsets (dh) within PBL at the indicated time-points and for total leukocytes in the spleen (i) and lin–ve/sca-1+ve/c-kit+ve HSPC) in BM (j) 26 weeks after BMT. Data show individual mice or mean ± SEM of results from a single experiment (a, b), mean ± SEM of results pooled from three or four experiments (ch) or individual mice with mean ± SEM pooled from three or four experiments (i, j). ANOVA with Tukey’s post test. BM bone marrow, BMT bone marrow transplant, HPC lin–ve/sca-1+ve/c-kit+ve HSPC

Back to article page